MedTrace Logo

Signaling Pathways Targeting Colorectal Cancer in Egypt

NCT03467308 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 180

Last updated 2020-05-11

No results posted yet for this study

Summary

Colorectal cancer (CRC) is the third most commonly diagnosed cancer and the second leading cause of cancer-related death worldwide. In Egypt, CRC constitutes 4.2% of all cancers with median age is 50 years old.

Conditions

Interventions

GENETIC

Markers in tissue samples: (TIGAR , TRIM59, P53, AKT, GSH)

The followings markers will be investigated in tissue samples: 1. TIGAR expression using quantitative real-time polymerase chain reaction (q Rt PCR) and immunohistochemistry. 2. TRIM59 expression using quantitative real-time polymerase chain reaction (q Rt PCR) and immunohistochemistry. P53 expression using immunohistochemistry. P53 nuclear localization is essential for its normal function in growth inhibition or induction of apoptosis. * Akt expression using western blot. * GSH using chemical methods.

Sponsors & Collaborators

  • Assiut University

    lead OTHER

Principal Investigators

  • Asmaa Alaaeldeen Kamal, MD (PhD student) · Assiut University

  • Ragaa Hamdy Salama, Professor (MD) · Assiut University

  • Maha Ali Essam al-Din, lecturer (MD) · Assiut University

  • Marwa AbdelHafiz Abdel Hassan, lecturer (MD) · Assiut University

  • Ahmed Ali Abdel Motelb, lecturer (MD) · Assiut University

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-03-01
Primary Completion
2020-01-01
Completion
2020-04-01

Countries

  • Egypt

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03467308 on ClinicalTrials.gov